Pfenex Inc (PFNX) Stock Price & Overview
NYSEARCA:PFNX
Current stock price
The current stock price of PFNX is 12.75 null. Today PFNX is down by -0.08%. In the past month the price increased by 1.03%. In the past year, price increased by 70.91%.
PFNX Key Statistics
- Market Cap
- 437.287M
- P/E
- N/A
- Fwd P/E
- 30.36
- EPS (TTM)
- -0.23
- Dividend Yield
- N/A
PFNX Stock Performance
PFNX Stock Chart
PFNX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PFNX. When comparing the yearly performance of all stocks, PFNX is one of the better performing stocks in the market, outperforming 93.5% of all stocks.
PFNX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PFNX. PFNX has an excellent financial health rating, but there are some minor concerns on its profitability.
PFNX Earnings
PFNX Forecast & Estimates
PFNX Financial Highlights
Over the last trailing twelve months PFNX reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -14.1% | ||
| ROA | -6.76% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PFNX Ownership
About PFNX
Company Profile
Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.
Company Info
Pfenex Inc
10790 ROSELLE STREET
SAN DIEGO CA 92121
CEO: Evert B. Schimmelpennink
Phone: 858-352-4400
Pfenex Inc / PFNX FAQ
Can you describe the business of Pfenex Inc?
Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.
What is the stock price of Pfenex Inc today?
The current stock price of PFNX is 12.75 null. The price decreased by -0.08% in the last trading session.
Does PFNX stock pay dividends?
PFNX does not pay a dividend.
What is the ChartMill rating of Pfenex Inc stock?
PFNX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is PFNX stock listed?
PFNX stock is listed on the NYSE Arca exchange.